All In MedTech

Device Trial Radar · NCT07728071

Evaluation of the Aulea Veloxion™ Disposable Resectoscope System for Operational Efficiency in Surgical Management of Benign Prostatic Hyperplasia (BPH)

Prospective, Single-Site, Single-Arm Evaluation of the Aulea Veloxion™ Disposable Resectoscope System for Operational Efficiency in Surgical Management of Benign Prostatic Hyperplasia (BPH)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Oct 2, 2026

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Chinese University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 27, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Male only, from 30 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, single-arm, single-site, post-market device study; all procedures use Veloxion™ per IFU.

Conditions

  • BPH (Benign Prostatic Hyperplasia)

Interventions

  • TURP using the Aulea Veloxion™ Disposable Resectoscope SystemProcedure

    TURP will be performed by Aulea Veloxion™ Disposable Resectoscope System. The resectoscopes are single-use and ensure consistent quality and no cross-contamination. The automated fluid management system continuously monitors and manages intravesical pressure while actively evacuating tissue to prevent clogging. The active power generation system optimize plasma generation for effective resection and extended equipment life. This system allows transurethral resection of prostate to be performed in a motorized and highly effective manner. This study is designed to prospectively characterize operational efficiency in real-world BPH resections using the cleared device platform.

  • Aulea Veloxion™ Disposable Resectoscope SystemDevice

    Veloxion™ platform disposable resectoscope is FDA-cleared for treatment of BPH. It is an all-in-one, platform that combines fluid control, video pipeline and energy generator. The resectoscopes are single-use and ensure consistent quality and no cross-contamination. The automated fluid management system continuously monitors and manages intravesical pressure while actively evacuating tissue to prevent clogging. The active power generation system optimize plasma generation for effective resection and extended equipment life. This system allows transurethral resection of prostate to be performed in a motorized and highly effective manner. This study is designed to prospectively characterize operational efficiency in real-world BPH resections using the cleared device platform.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in total procedure time versus a pre-specified benchmarkTime frame: Perioperative
  2. Difference in case cost versus a pre-specified benchmarkTime frame: Perioperative

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Prince of Wales Hospital

    Shatin, Hong Kong · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.